43 results about "Controlled pain" patented technology

A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.

The present invention discloses novel compounds of general formula (I)

or a pharmaceutically acceptable salt or prodrug thereof (in which X₁—X₅, R₅—R_8b, Z₁-Z₂ and Ar₁ are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Disclosed is a method of inducing topical anesthesia in a tissue or organ of an animal comprising providing an aqueous gel formulation comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed are a transdermal patch comprising the aqueous gel formulation suitable for applying on the skin of a patient and a method of controlling pain therewith.

The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous GlyR protein (an ion channel) in response to the allosteric modulator modulates the electrophysiological activity of the excitable cell. The method can be used to control pain in a subject. The invention further provides a replication-defective HSV vector comprising an expression cassette encoding a GlyR protein, stocks and pharmaceutical compositions containing such vectors, and a transgenic animal.

Disclosed are a combination of active components inducing synergistic effects of multi-targeting and a use thereof. More particularly, disclosed are a functional food composition, a cosmetic composition, a pain-suppressive composition, and a composition for treatment or prevention of pruritus or atopic dermatitis, which comprise as active components, two or more components selected from a group consisting of (a) a 5-hydroxytryptamine subtype 2 (5-HT2) receptor antagonist; (b) a P2X receptor antagonist; and (c) any one of a glycine receptor agonist, a glycine transporter (GlyT) antagonist, a gamma-aminobutyric acid (GABA) receptor agonist, and a GABA transporter 1 (GAT1) antagonist. The multi-targeting composite composition (specifically, natural substances composite composition) has synergistic effects, and thus a treatment using a combination of respective components may achieve increased biological effects, in which mechanisms targeted by respective components are involved. Thus, the multi-targeting composite composition may not only remarkably control pain but may also increase effects of: alleviating symptoms of skin diseases such as itching and atopic dermatitis; preventing or improving depression, refreshment, pore minimization, improving wrinkles, skin regeneration, skin health, recovery of skin condition, skin whitening, preventing or improving athlete's foot, recovery of scalp health and regeneration of scalp, promoting hair growth, preventing gray hair, and improving dental and periodontal diseases, etc.

A method for substantially reducing the range in daily dosages required to control pain in approximately. 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean,of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour): administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.

The present disclosure provides compositions and methods for controlling pain. The present disclosure provides methods for identifying agents that control pain.

An extended release analgesic for controlling pain comprised of an opioid or non-opioid analgesic drug ionically bound to hyaluronic acid, poly-γ-glutamic acid or other ionic polymers, and injected into a body either subcutaneously, intramuscularly or intraperitoneally, utilizing counter-ions of different valences to control the rate of release into the body.

A process and laser system for in vitro and in vivo pain research, pain clinical testing and pain management. In preferred embodiments of the present invention a diode laser operating at a 980 nm wavelength is used to produce warmth, tickling, itching, touch, burning, hot pain or pin-prick pain. The device and methods can be used for stimulation of a single nerve fiber, groups of nerve fibers, nerve fibers of single type only as well as more the one type of nerve fibers simultaneously. The present invention is especially useful for research of human/animal sensitivity, pain management, drug investigation and testing, and psychophysiology/electrophysiology studies. The device and methods permit non-contact, reproducible and controlled tests that avoid risk of skin damage. Applicant an his fellow workers have shown that tests with human subjects with the process and laser of the present invention correlate perfectly with laboratory tests with nerve fibers of rats. The device and the methods can be applied in a wide variety of situations involving the study and treatment of pain. Preferred embodiments of the present invention provide laser systems and techniques that permit mapping and single mode activation of C fibers and A-delta fibers.

The present invention provides a therapy instrument for myocardial ischemia, which is combined with power circuit, generation circuit of modulation wave, shaping circuit of modulation wave, modulation circuit, constant current source circuit, stimulating electrode, CPLD carrier generation circuit, carrier shaping circuit, output intensity control circuit and MCU. The therapy instrument has characters of non-invasive, non-pain sense electrical stimulation, overcoming body adaptability etc., and can treat patient with comfortable sense. The therapy instrument can assistant treat myocardial ischemia by skin spinal cord and fastigial nucleus electrical stimulation. The therapy instrument modulates the random signal of low-frequency slow change rhythm on the MF carrier signal with special spectrum structure by method of pulse amplitude modulation, and loads LF current to human skin spinal cord and fastigial nucleus with forms of current by surface electrode. The therapy instrument can treat myocardial ischemia by improving coronary blood flow, reducing myocardial oxygen consumption, controlling pain and protecting neurogenic neuroprotection.

The present invention discloses systems and methods for stimulation of the trigeminal nerve via indirect application of micro-current from a self-contained frequency/static-charged device. The device is treated with a process that allows it to store and dispense a low-level charge. The device can be directly or indirectly infused with a frequency from an external charging system; embedded with a charge-sustaining supplement and infused with a frequency that can be transferred from an external charging system, or embedded with a frequency generating and sustaining component, without infusion from an external charging system. The device operates independently once infused or embedded with operational frequency. The device is positioned near one or more trigeminal access point such as intra-oral, temple, or neck. The device may be used to increase strength, flexibility, balance, calm heart rate, and help control pain. Usage encourages neural plasticity, establishing sustainable new connections between nerve cells.

The invention relates to a traditional Chinese medicine for treating pain and a preparation method of the traditional Chinese medicine, in particular to a traditional Chinese medicine compound pain resisting medicine and a preparation method thereof. The recipe comprises the following materials: nux vomica, lumbricus, garden balsam stem, stiff silkworm, fourstamen stephania root, radix clematidis, Chinese angelica, raw rhubarb, herba lycopi, frankincense, myrrh, drynaria baronii, cowherb seed, asarum sieboldii, cortex acanthopanacis senticosus, herba siegesbeckiae, Chinese holly leaf, centipede, loofah sponge, ephedra and the like. The preparation method comprises the following steps: taking 2,000 ml of sesame oil into a pot, putting the materials into the pot, carrying out deep frying, removing slag, refining oil, dropping water to be bead, feeding 1,000 g of minium, and stirring. Through the adoption of traditional Chinese medicine ointments and medicines for external use, the medicine resistance and toxic and side effects generated after oral taking of Western medicines or chemical agents are solved, pain and inconvenience brought for a patient due to injection treatment are avoided, the pain symptoms of the patient are solved, the pain of the patient is reduced, and the functions of warming channel, dredging collaterals, relaxing muscles, stimulating blood circulation and stopping pain can effectively control pain seizure.

A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.

The present invention pertains to a non-invasive method and apparatus for predicting or monitoring analgesia and blood levels of opioid drugs in a patient receiving pain treatment, e.g., during palliative treatment. The inventive method comprises the measurement of one or more, preferably two or more, surrogate markers of a patient. According to the present invention surrogate markers correlate with the level of analgesia in the opioid receiving subject and thus provide a non-invasive method to predict and monitor analgesia during a treatment. Even more, surrogate markers were identified which correlate with the blood-concentration of the opioid in the subject. Thus, the invention provides a valuable clinical tool to assess and control pain treatments with opioids. Disclosed is the prediction method, an apparatus suitable for performing the inventive methods as well as the apparatus for use in medical treatments, such as pain therapy.

An electronic stimulation system is used to control pain over multiple regions of a patient's body. The system has one or more percutaneous leads, each having multiple electrodes, implanted within the patient's epidural space parallel to the axis of the spinal cord. The leads are connected to either a totally implanted system or a radio frequency system. The system is able to treat pain over different regions of a patient's body by “simultaneously” stimulating the patient with at least three different stimulation settings. “Simultaneous” stimulation involves sequentially stimulating the patient with the multiple stimulation settings such that the patient receives the cumulative effect of each stimulation setting, while not perceiving the transition from one stimulation setting to another.

The invention discloses an arthralgia and myalgia patch and a manufacturing method thereof. An ointment comprises, by weight, 290-310 parts of Chinese clematis roots, 115-135 parts of Chinese angelicaroots, 115-135 parts of fortune's drynaria rhizomes, 25-35 parts of incised notopterygium rhizomes and roots, 25-35 parts of doubleteeth pubescent angelica roots,55-56 parts of chuanxiong rhizomes, 25-35 parts of Himalayan teasel roots, 25-35 parts of medicinal cyathula roots, 25-35 parts of tall gastrodia rhizomes, 5-15 parts of pangolin scales, 25-35 parts of slenderstyle acanthopanax roots andbarks, 5-15 parts of dragon's blood, 25-35 parts of Solamum melongena, 15-25 parts of prepared Chinese monkshood roots, 15-25 parts of prepared kusnezoff monkshood roots, 25-35 parts of fresh reddishjackinthepulpit rhizomes, 25-35 parts of fresh ternate pinellia rhizomes, 25-35 parts of white mulberry barks, 25-35 parts of dahuria gentian roots, 25-35 parts of olibanum, 90-110 parts of borneol,25-35 parts of camphor and 10 parts of wild mint oil. A formula of the paste can effectively control pain, restrain hyperostosis and treat bone diseases. According to the manufacturing method of the paste, 90% of effective components are extracted through ethyl alcohol, effective components in medicinal materials can be efficiently extracted through an extracting process, the utilization ratio ofthe medicinal materials is increased, and cost is reduced.